Clinical observation of capecitabine and temozolomide in the treatment of advanced pancreatic neuroendocrine tumors / 中国肿瘤临床
Chinese Journal of Clinical Oncology
; (24): 228-232, 2017.
Article
in Zh
| WPRIM
| ID: wpr-509734
Responsible library:
WPRO
ABSTRACT
Objective:
To observe the therapeutic effect and toxicity of capecitabine and temozolomide in the treatment of advanced pancreatic neuroendocrine tumors.Methods:
A total of 14 patients with stageⅣwell-differentiated pancreatic neuroendocrine tumor (NET G1/G2/G3) were treated with oral CAPTEM regimen, and the response rate, PFS and adverse effect after treatment were analyzed. All data analyses were performed using software SPSS17.0.Results:
These 14 patients were followed-up for more than 2 years. Till Oct 2016, one patient got CR, one patient got PR, four patients got SD. Median progression-free survival was 8.9 months. The two year survival rate was 85.7%. Only one patient experienced grade 3 adverse events.Conclusion:
CAPTEM is an effective and well-tolerated salvage regimen for the treatment of advanced well-differentiated pNET.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Clinical Oncology
Year:
2017
Type:
Article